Skip to main content
Download PDF

Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training

Diabetology & Metabolic Syndrome volume 13, Article number: 36 (2021) Cite this article

Abstract

Aim

Gut leakage has been shown to associate with low-grade inflammation and lower cardiorespiratory fitness in diabetic subjects. We aimed to investigate whether gut leakage markers related to cardiorespiratory fitness in patients with both coronary artery disease and type 2 diabetes, and whether these were affected by long-term exercise training.

Methods

Patients with angiographically verified coronary artery disease and type 2 diabetes mellitus (n = 137) were randomized to either 12 months exercise intervention or conventional follow-up. A cardiopulmonary exercise test and fasting blood samples were obtained before and after intervention to assess VO2peak and the biomarkers soluble CD14, lipopolysaccharide-binding protein and intestinal fatty-acid binding protein as markers of gut leakage.

Results

114 patients completed the intervention satisfactory. VO2peak correlated inversely to sCD14 (r = − 0.248, p = 0.004) at baseline. Dividing sCD14 into quartiles (Q), VO2peak was significantly higher in Q1 vs. Q2–4 (p = 0.001), and patients in Q2-4 (sCD14 > 1300 ng/mL) had an OR of 2.9 (95% CI 1.2–7.0) of having VO2peak below median (< 23.8 ml/kg/min) at baseline. There were no statistically significant differences in changes in gut leakage markers between the two randomized groups (all p > 0.05) after 12 months.

Conclusions

Cardiorespiratory fitness related inversely to sCD14, suggesting physical capacity to be associated with gut leakage in patients with CAD and T2DM. Long-term exercise training did not affect circulating gut leakage markers in our population.

Trial registration NCT01232608, Registered 02 November 2010—Retrospectively registered at https://clinicaltrials.gov/ct2/show/NCT01232608?term=NCT01232608&draw=2&rank=1

Introduction

Intestinal dysbiosis and gut leakage is hypothesized to contribute to the chronic low-grade inflammatory state associated with obesity, insulin resistance and atherosclerotic cardiovascular disease (CVD) [1, 2]. Gut leakage describes the translocation of bacterial wall products, mainly lipopolysaccharide (LPS), across the gut barrier by either para- or transcellular mechanisms, or by enterocyte damage with subsequent leakage of the intracellular intestinal fatty acid-binding protein (I-FABP) into the circulation [3]. LPS in the circulation interacts with LPS-binding protein (LBP), membrane bound or soluble CD14 (sCD14), activating the toll-like receptor 4 (TLR4) and initiating downstream inflammatory signaling [4]. Elevated levels of LBP and sCD14 have been associated not only with insulin resistance and obesity [5], but also with coronary artery disease (CAD) and all-cause mortality [6, 7]. As levels of LBP and sCD14 have been shown to correlate with LPS, they are acknowledged surrogate markers for endotoxemia [8]. However, an increase in sCD14 is not restricted to LPS exposure, but can be regarded as a marker of monocyte activation [9]. I-FABP is regarded as a marker of intestinal injury or ischemia [10].

Regular physical exercise is recommended by the European society of Cardiology for prevention of cardiovascular events and all-cause mortality, and is associated with a beneficial cardio-metabolic profile and decrease in markers of systemic inflammation [11]. Furthermore, a combination of aerobic and resistance training has been shown to improve insulin sensitivity and glycemic control in subjects with T2DM [12]. Exercise has also been hypothesized to contribute to increased gut microbial diversity, and thus a less leaky gut [13]. In healthy subjects, microbial diversity has been shown to associate with cardiorespiratory fitness [14], whereas in diabetic and pre-diabetic subjects gut leakage markers have been reported elevated, and importantly, modifiable by exercise [15]. However, the link between physical fitness and effects of exercise training on markers of gut leakage has not been extensively studied, particularly in patients with CAD. Our aims were therefore to explore the relationship between cardiorespiratory fitness and gut leakage markers in patients with combined CAD and T2DM. We hypothesized that less aerobically fit patients have higher levels of gut leakage markers than fit patients. Secondly, we aimed to investigate whether long-term exercise can impact circulating gut leakage markers in patients with T2DM and CAD. Our hypothesis was that exercise would reduce gut leakage.

Methods

Study population

The present investigation is a sub-study of the “Exercise training in patients with coronary artery disease and type 2 diabetes” (EXCADI) study [16]. Patients with combined T2DM and angiographically verified CAD (n = 137) were included at Department of Cardiology, Oslo University Hospital, Oslo, Norway, between August 2010 and March 2012. The study design has previously been described in detail, and the methods description partly reproduces their wording [16]. In brief, patients were randomized 1:1 to a combination of strength and endurance training with an instructor or to a control group with conventional follow-up by their general practitioner. Patients in the control group were not discouraged to exercise. Diabetic microvascular complications were defined as a history of nephron-, neuro- or retinopathy, and/or abnormal monofilament test and/or (micro-) albuminuria. Patients with previous myocardial infarction (MI) and/or diabetic complications were defined to have advanced vascular disease. Hypertension (HT) was defined as use of antihypertensive medication.

Exclusion criteria were presence of proliferative retinopathy, end-stage renal disease, cancer, stroke or acute MI within the last 3 months, unstable angina, decompensated heart failure, serious arrhythmia, severe valvular disease, severe rheumatologic disease, chronic obstructive pulmonary disease stadium GOLD IV, thromboembolic disease, ongoing infections, severe musculoskeletal disorders, or other disabilities limiting the ability for physical activity.

Cardiopulmonary exercise test

A cardiopulmonary exercise test using a modified Balke protocol was performed on treadmill before the intervention and approximately one week after the last exercise session [17]. The procedure has previously been described [18]. It was continued until exhaustion or until ended by the physician for safety reasons. Gas exchange was continuously measured by breathing into a Hans Rudolph two-way breathing mask (2700 series; Hans Rudolph Inc, Kansas City, USA), connected to a metabolic cart (Vmax SensorMedics, Yorba Linda, USA) assessing ventilation, oxygen and carbon dioxide content of expired air. VO2peak was defined as the highest average oxygen uptake of consecutive 30 s during the test. The achieved VO2peak was also included if the test had to be terminated because of functional limitations. Maximal respiratory exchange ratio (RER) was measured. The anaerobic threshold (AT) was estimated by the ventilatory equivalent method [19].

Physical exercise intervention

The exercise group underwent a 12-month training intervention. The physical exercise program was developed and conducted in collaboration with the Norwegian School of Sport Sciences (NIH). Details on the exercise program have previously been described [16]. In brief, the exercise group participated in a total of 150 min of training per week, divided into supervised group-based training sessions of combined aerobic and resistance training two times a week, with an additional home-based individual exercise once a week. The Borg’s rated perceived exertion (RPE) scale was used to guide exercise intensity [20].

Laboratory methods

Venous blood samples were drawn in fasting conditions by standard venipuncture between 08:00 and 10:00 a.m. before intake of morning medication at time of inclusion and after 1 year. Routine blood samples including HbA1, insulin, CRP and C-peptide were determined by conventional laboratory methods. Insulin resistance was estimated by the updated homeostatic model assessment indexes for insulin resistance (HOMA2-IR). Glucose and insulin values were entered in the computer model to calculate HOMA2-IR [21].

A biobank was established. Serum was prepared by centrifugation within 1 h at 2500g for 10 min, and EDTA plasma was prepared by centrifugation within 1 h at 2700g for 20 min at 4 °C, both kept frozen at − 80 °C until analyses. I-FABP was determined in serum, measured by enzyme-linked immunosorbent assay (ELISA) (Hycult Biotech, Uden, the Netherlands). sCD14 and LBP were measured in EDTA plasma by ELISAs (R&D Systems Europe, Abingdon, Oxon, UK and Hycult Biotech, respectively). The inter-assay coefficients of variation (CV) were 17.3%, 10.9% and 8.1% respectively.

Statistical analysis

Demographic data are given as proportions, mean (± SD) or median (25th and 75th percentiles) depending on the data distribution. Differences between groups at baseline were analyzed by Chi square test for categorical data and Mann–Whitney U test or Kruskal–Wallis Test as appropriate for continuous data. Correlation analyses were performed by Spearman’s Rho. A univariate logistic regression model was used to estimate odds ratio for peak VO2 according to levels of sCD14, and a multivariate regression analysis was used to adjust for variables known to influence peak VO2 (age, sex and BMI). Receiver operating characteristic (ROC) curve was performed to explore any predictive value of I-FABP1 for the presence of microvascular complications. Changes in biomarkers from baseline to end of intervention are given as absolute and relative changes. Within-group changes were analyzed by Wilcoxon Signed Rank test, and differences in changes and relative changes between groups were analyzed by Mann–Whitney U test. Statistical calculations were performed using SPSS version 25 (SPSS, Inc., Chicago, IL, USA). p-values < 0.05 were considered statistically significant.

Results

Patient characteristics at baseline

Baseline characteristics are presented in Table 1. Of the 137 included patients, 123 completed the study. Patients with the lowest adherence to the training intervention (< 40% adherence) were excluded (n = 9) from the per protocol analyses [16]. Thus, 114 patients were analyzed for the

Table 1 Baseline characteristics of the total population and according to randomized groups
Full size table

intervention effect; 52 in the exercise group and 62 in the control group. There were no significant differences between the intervention groups at baseline.

There were no significant differences between the groups in changes in weight, waist circumference, energy intake, percentage intake of main nutrients or diabetes medication during the study period, as previously reported [16]. There was also no significant difference in basal metabolic rate (BMR) between the groups at baseline or significant difference in change between the groups after the intervention (data not shown).

Gut-related biomarkers and cardiorespiratory fitness at baseline

As outlined in Table 2, the intervention groups were comparable as to physical performance at baseline. During the cardiorespiratory exercise test, one hundred and twenty-seven patients (93%) reached RER > 1.10 and/or Borg scale (6–20) > 17. Levels of the gut leakage markers at baseline are also presented in Table 2. The gut leakage markers did not differ between the two randomized groups at baseline.

Table 2 Physical performance and levels of gut leakage markers in all patients, and according to intervention groups at baseline
Full size table

In the total population, VO2peak was inversely correlated to sCD14 (p = 0.004) (Table 3, Additional file 2: Figure S1) and CRP (r = − 0.320, p < 0.001). Otherwise, no significant correlations between markers of gut-related inflammation and variables reflecting physical performance were observed.

Table 3 Coefficients of correlation between gut leakage markers and physical fitness at baseline
Full size table

VO2peak levels differed significantly between quartiles of sCD14 (p = 0.005) (Fig. 1). Based on a visual cut-off between the lowest quartile (Q1) and the three highest quartiles (Q2–4) (Fig. 1, arrow), sCD14 was dichotomized into Q1 and Q2–4 for further analyses. VO2peak was significantly lower in Q2–4 compared to Q1 (p = 0.001) (Fig. 2). Patients in Q2–4 (sCD14 > 1300 ng/mL) had an odds ratio (OR) of 3.2 (95% CI 1.4–7.5) of having a VO2peak below median (< 23.8 mL/kg/min). The results were still significant after adjusting for age, sex and BMI, with an OR of 2.9 (95% CI 1.2–7.0).

Fig. 1
figure 1

VO2peak in quartiles of sCD14. Q1: < 1300 ng/mL Q2: 1300–1504 ng/mL Q3: 1504–1759 ng/mL Q4: > 1759 ng/mL (error bars indicate 25th, 75th percentiles). Arrow indicates cut off level

Full size image
Fig. 2
figure 2

VO2peak in dichotomized groups of sCD14 (error bars indicate 25th, 75th percentiles). p-value is given for difference between groups

Full size image

Markers of gut leakage, glucometabolic state and diabetic complications

Levels of sCD14 at baseline correlated significantly to fasting blood glucose (r = 0.174, p = 0.044), but not to HbA1c, HOMA2-IR and diabetes duration (Additional file 1: Table S1). LBP correlated significantly to waist circumference (r = 0.198, p = 0.023), but not to any glucometabolic variable. Patients with microvascular complications had significantly higher I-FABP than patients without these diabetic complications (p = 0.010), with an AUC of 0.66 (95% CI 0.56, 0.77) in ROC curve analysis (p = 0.010).

Effect of exercise on markers of gut leakage

Changes in markers of gut leakage according to the intervention groups from baseline to 12 months are illustrated in Fig. 3. Relative changes during the intervention are presented in Fig. 4. As previously reported, there was a non-significant increase in mean VO2peak in the exercise group of 0.8 mL/kg/min (95% CI − 0.2 to 1.8; p = 0.107), and the difference in change from baseline to 12 months was not significant between the exercise group and the control group [16]. The exercise intervention did not significantly affect the gut leakage markers after 12 months, neither in absolute nor in relative numbers (Figs. 3 and 4). The same lack of intervention effect was observed for patients without advanced vascular disease (n = 46). For patients in the intervention group who increased their VO2peak numerically during the intervention period (n = 28), no significant changes in gut leakage markers were observed (data not shown).

Fig. 3
figure 3

Median changes in gut leakage markers from baseline to 12 months in the randomized groups in absolute values (error bars indicate 25th, 75th percentiles). ∆p-values refer to difference in change between groups

Full size image
Fig. 4
figure 4

Relative changes in gut leakage markers from baseline to 12 months in the randomized groups. The relative changes are presented as median (error bars indicate 25th, 75th percentiles). Rel ∆p-values refer to difference in change between groups

Full size image

There were no significant within group changes from baseline to 12 months in any of the gut leakage markers, neither in the exercise nor the control group (data not shown).

Discussion

This study aimed to explore the relationship between cardiorespiratory fitness and markers of gut leakage in patients with combined T2DM and CAD. Our main finding was a significant inverse association between VO2peak and levels of sCD14 and CRP, indicating increased monocyte activation and inflammation, and possibly increased gut leakage, in individuals with poorer cardiorespiratory fitness. We did not, however, find any significant association with LBP, which is a more robust marker of gut leakage. There was no significant effect of 12 months exercise intervention on levels of gut leakage markers. This is, to the best of our knowledge, the first report on the relationship between cardiorespiratory fitness and gut leakage markers in patients with combined T2DM and CAD.

Although we did not measure the gut microbial composition or LPS levels per se, LPS is a potent stimulator of sCD14 release [22]. Our result showing low cardiorespiratory fitness to be associated with high levels of sCD14 could indicate a relationship to a dysbiotic and leaky gut. sCD14 has, however, been shown to be released upon interaction with other TLR ligands and inflammatory cytokines as well [9], and could therefore be considered a marker of monocyte activation and inflammation in general, not necessarily restricted to LPS and TLR4 interaction. The observed similar inverse relationship between CRP and VO2peak in our patients supports the theory of a general inflammatory process.

The underlying mechanisms by which a dysbiotic intestinal microbiota, gut leakage and cardiorespiratory fitness interact remain vastly unexplained. Our cross-sectional study of the baseline association limits our possibility of suggesting any causality, but previous studies link both intestinal dysbiosis and low cardiorespiratory fitness to a state of low-grade inflammation [2, 23]. Chronic inflammation is also present in obesity [24], but our findings were significant even after adjusting for BMI. Collectively, these results allow us to speculate that change in gut permeability and subsequent gut leakage is linked to the activation of inflammatory signaling pathways, being relevant in T2DM, atherosclerosis and cardiorespiratory fitness. However, one cannot rule out the possibility that patients with higher inflammation have greater cytokine-induced fatigue and are less likely to exercise, and therefore have lower baseline VO2peak and higher sCD14.

Beyond significant higher levels of I-FABP in patients with microvascular complications, the investigated gut leakage markers did not correlate to glucose control or any marker of glucometabolic state, except for a significant association between sCD14 and fasting blood glucose (p = 0.044). The significant correlation found between LBP and waist circumference, is in line with previous studies reporting LBP to be elevated in obesity and in patients with an unhealthy adipose tissue distribution [25].

Effect of exercise training

There were no significant changes in any of the gut leakage markers after 12 months of combined resistance and endurance training. We have previously reported that the exercise group overall did not improve their VO2peak, whereas patients without advanced vascular disease did [16]. As we found sCD14 linked to cardiorespiratory fitness, we hypothesized that levels of sCD14 would be reduced in those who increased their VO2peak during the exercise period, but no such relationship was found. It is possible that this group of patients, with both CAD and several years of diabetes with various macro- and microvascular complications, had too advanced disease to reach the presumed effect on reduction in gut leakage markers after 12 months. We could, however, not find any effect of exercise on the gut leakage markers when analyzing patients without advanced vascular disease separately.

The lack of intervention effect in the current study could also be due to lack of power, as power calculations were not specifically performed for the present hypothesis. It may also have been affected by the extent of exercise adherence, which was quite low, with an average of 67% (55%, 83%) [16]. However, it is unclear how much exercise is needed for patients to benefit from it, although we do know that 150/min per week is recommended on a general basis for patients with T2DM [26], and supervised combined resistance and endurance training has been shown to be the best [27].

Our patients were all on medication, of which several are known to have immunomodulary effects to some extent. Almost 74% of the patients were on metformin that has been shown to have a variety of immunomodulatory effects [28]. Although the mechanisms of action and clinical relevance are unclear, and we found no significant difference between patients on and without metformin (data not shown), it is possible that any exercise effect on levels of gut leakage and inflammation, could be masked by metformin usage. In addition, over 90% were on aspirin, known to have anti-inflammatory effects [29], and 35% were on sulfonylureas, which also seem to possess anti-inflammatory properties [30]. This might have modulated the inflammatory response to LPS exposure in our patients, and could have attenuated the measurable effect of the exercise intervention.

Limitations

The main limitation of our study is that it was initially designed for the purpose of studying the effect of exercise training on HbA1c [16], thus not for considering effects on the investigated gut leakage markers. Although patients with ongoing infections were excluded from the study at baseline, there was no exclusion of patients who had used antibiotic treatment in the months prior to inclusion. Other studies have excluded patients using antibiotics up to 6 months prior to inclusion [14]. We have not measured levels of LPS, which may have added to the results. However, LPS is unstable in the circulation, and the most used laboratory method for LPS quantification, the limulus amebocytes lysate assay, is encumbered with limitations. We also did not analyze the interventional effects on the microbiota itself. Finally, although we know that different diets alter the gut microbiota differently, we did not control the participants’ diet in details during the intervention [31].

Conclusion

The inverse association demonstrated between VO2peak and levels of sCD14 and CRP, suggests a significant interaction between cardiorespiratory fitness and gut-related inflammation in our patients with both type 2 diabetes and coronary artery disease.

A 12 months exercise intervention program did, however, not affect gut leakage markers in this patient group.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

CAD:

Coronary artery disease

CVD:

Cardiovascular disease

T2DM:

Type 2 diabetes mellitus

VO2peak :

Peak oxygen uptake

sCD14:

Soluble cluster of differentiation 14

LPS:

Lipopolysaccharide

LBP:

LPS-binding protein

I-FABP:

Intestinal fatty-acid binding protein

TLR4:

Toll-like receptor 4

GOLD:

Global initiative for chronic obstructive lung disease

MI:

Myocardial infarction

AT:

Anaerobic threshold

RER:

Respiratory exchange ratio

RPE:

Rated perceived exertion

ELISA:

Enzyme-linked immune sorbent assay

HOMA2-IR:

Updated homeostatic model assessment of insulin resistance

SCFA:

Short chain fatty acid

EXCADI:

Exercise training in patients with coronary heart disease and Type 2 diabetes

References

  1. Ascher S, Reinhardt C. The gut microbiota: an emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol. 2018;48(4):564–75.

    Article  CAS  Google Scholar 

  2. Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology. 2016;31(4):283–93.

    Article  CAS  Google Scholar 

  3. Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020. https://doi.org/10.1210/jendso/bvz039.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Płóciennikowska A, Hromada-Judycka A, Borzęcka K, Kwiatkowska KJC, Sciences ML. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72(3):557–81.

    Article  Google Scholar 

  5. Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes. 2012;36(11):1442–9.

    Article  CAS  Google Scholar 

  6. Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol. 2013;33(1):158–64.

    Article  CAS  Google Scholar 

  7. Lepper PM, Schumann C, Triantafilou K, Rasche FM, Schuster T, Frank H, et al. Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol. 2007;50(1):25–31.

    Article  CAS  Google Scholar 

  8. Battson ML, Lee DM, Weir TL, Gentile CL. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 2018;56:1–15.

    Article  CAS  Google Scholar 

  9. Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS. 2015;29(10):1263–5.

    Article  CAS  Google Scholar 

  10. Timmermans K, Sir O, Kox M, Vaneker M, de Jong C, Gerretsen J, et al. Circulating iFABP levels as a marker of intestinal damage in trauma patients. Shock. 2015;43(2):117–20.

    Article  CAS  Google Scholar 

  11. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.

    Article  Google Scholar 

  12. Codella R, Ialacqua M, Terruzzi I, Luzi L. May the force be with you: why resistance training is essential for subjects with type 2 diabetes mellitus without complications. Endocrine. 2018;62(1):14–25.

    Article  CAS  Google Scholar 

  13. Monda V, Villano I, Messina A, Valenzano A, Esposito T, Moscatelli F, et al. Exercise modifies the gut microbiota with positive health effects. Oxid Med Cell Longev. 2017;2017:3831972.

    Article  Google Scholar 

  14. Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016;4(1):42.

    Article  Google Scholar 

  15. Motiani KK, Collado MC, Eskelinen JJ, Virtanen KA, LÖyttyniemi E, Salminen S, et al. Exercise training modulates gut microbiota profile and improves endotoxemia. Med Sci Sports Exerc. 2020;52(1):94–104.

    Article  Google Scholar 

  16. Byrkjeland R, Njerve IU, Anderssen S, Arnesen H, Seljeflot I, Solheim S. Effects of exercise training on HbA1c and VO2peak in patients with type 2 diabetes and coronary artery disease: a randomised clinical trial. Diab Vasc Dis Res. 2015;12(5):325–33.

    Article  Google Scholar 

  17. Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. UN Armed Forces Med J. 1959;10(6):675–88.

    CAS  Google Scholar 

  18. Byrkjeland R, Edvardsen E, Njerve IU, Arnesen H, Seljeflot I, Solheim S. Insulin levels and HOMA index are associated with exercise capacity in patients with type 2 diabetes and coronary artery disease. Diabetol Metab Syndr. 2014;6(1):36.

    Article  Google Scholar 

  19. Wasserman K. Principles of exercise testing and interpretation : including pathophysiology and clinical applications. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.

    Google Scholar 

  20. Borg GA. Perceived exertion. Exerc Sport Sci Rev. 1974;2:131–53.

    Article  CAS  Google Scholar 

  21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.

    Article  Google Scholar 

  22. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA. 1993;90(7):2744–8.

    Article  CAS  Google Scholar 

  23. Wedell-Neergaard A-S, Krogh-Madsen R, Petersen GL, Hansen ÅM, Pedersen BK, Lund R, et al. Cardiorespiratory fitness and the metabolic syndrome: roles of inflammation and abdominal obesity. PloS ONE. 2018;13(3):e0194991.

    Article  Google Scholar 

  24. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.

    Article  CAS  Google Scholar 

  25. Awoyemi A, Troseid M, Arnesen H, Solheim S, Seljeflot I. Markers of metabolic endotoxemia as related to metabolic syndrome in an elderly male population at high cardiovascular risk: a cross-sectional study. Diabetol Metab Syndr. 2018;10:59.

    Article  Google Scholar 

  26. Marwick TH, Hordern MD, Miller T, Chyun DA, Bertoni AG, Blumenthal RS, et al. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(25):3244–62.

    Article  Google Scholar 

  27. Pan B, Ge L, Xun YQ, Chen YJ, Gao CY, Han X, et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Int J Behav Nutr Phys Act. 2018;15(1):72.

    Article  Google Scholar 

  28. Minamii T, Nogami M, Ogawa W. Mechanisms of metformin action: in and out of the gut. J Diabetes Investig. 2018;9(4):701–3.

    Article  Google Scholar 

  29. Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots—a concise summary. Vascul Pharmacol. 2019;113:1–8.

    Article  CAS  Google Scholar 

  30. Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol. 2019;234(6):8286–94.

    Article  CAS  Google Scholar 

  31. Moreira APB, Texeira TFS, Ferreira AB, Peluzio MdCG, Alfenas RdCG. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr. 2012;108(5):801–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors want to thank Ida Unhammer Njerve, Vibeke Bratseth, Sissel Åkra, Jeanette Konstanse Steen and Elisabeth Edvardsen for valuable contributions to the study.

Funding

This work was supported by the Stein Erik Hagen Foundation for Clinical Heart Research; and the Ada og Hagbart Waages Humanitære og Veldedige Stiftelse, Oslo, Norway. The funding source had no involvement in any part of the study or in the scientific writing, nor in the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Ullevål Pb 4956 Nydalen, 0424, Oslo, Norway

    Susanne Kristine Aune, Rune Byrkjeland, Svein Solheim, Harald Arnesen, Ayodeji Awoyemi, Ingebjørg Seljeflot & Ragnhild Helseth

  2. Faculty of Medicine, University of Oslo, Oslo, Norway

    Susanne Kristine Aune, Harald Arnesen, Marius Trøseid, Ayodeji Awoyemi & Ingebjørg Seljeflot

  3. Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway

    Svein Solheim, Ingebjørg Seljeflot & Ragnhild Helseth

  4. Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway

    Marius Trøseid

Authors
  1. Susanne Kristine Aune
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rune Byrkjeland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Svein Solheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harald Arnesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marius Trøseid
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ayodeji Awoyemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ingebjørg Seljeflot
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ragnhild Helseth
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SKA contributed to planning of the study, did most of the laboratory work, statistical analyses, interpretation of results and prepared the initial draft of the manuscript. RB was a major contributor in the conduction of the EXCADI study and to the intellectual content and discussion of the manuscript. SS and HA contributed in the planning of the study and to the intellectual content and discussion of the manuscript. MT contributed to the planning of the laboratory analyses, to the interpretation of the results and to the intellectual content and discussion of the manuscript. AA contributed to the intellectual content and discussion of the manuscript. IS and RH were major contributors in the planning and conduction of the study, statistical analysis, interpretation of the results and the intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Susanne Kristine Aune.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Regional Committee of Medical Research Ethics in South-Eastern Norway and conducted in accordance with the Declaration of Helsinki, and is registered at http://www.clinicaltrials.gov NCT01232608. All patients gave their written informed consent to participate.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

: Table S1. Baseline correlations between markers of gut leakage and glucometabolic state are presented in this table.

Additional file 2

: Figure S1. Correlation plot between VO2peak and sCD14 at baseline.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aune, S.K., Byrkjeland, R., Solheim, S. et al. Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training. Diabetol Metab Syndr 13, 36 (2021). https://doi.org/10.1186/s13098-021-00655-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13098-021-00655-2

Keywords

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us